Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mechanistic target of rapamycin (mTOR) inhibitors show promise for hematological malignancies.
• Rapamycin analogs are approved for mantle cell lymphoma but have limited efficacy in other blood cancers.
• ATP-competitive mTOR inhibitors offer more complete inhibition and efficacy in preclinical models.

Purpose of the Study:

• To investigate resistance mechanisms to active-site mTOR inhibitors in hematological malignancies.
• To identify specific molecular alterations driving resistance in lymphoma cell lines.
• To explore therapeutic strategies to overcome resistance.

Main Methods:

• Screening of diffuse large B-cell lymphoma cell lines for resistance to active-site mTOR inhibitors.
• Mechanistic investigation of the VAL cell line, identified as resistant.
• Analysis of eukaryotic initiation factor 4E-binding protein-1 (4EBP1) and its role in translation regulation.
• Assessment of sensitization to apoptosis upon knockdown of eukaryotic initiation factor 4E or re-expression of 4EBP1.

Main Results:

• The VAL cell line demonstrated significant resistance to apoptosis induced by active-site mTOR inhibitors.
• VAL cells lack expression of eukaryotic initiation factor 4E-binding protein-1 (4EBP1).
• Despite 4EBP2 expression, mTOR inhibition did not displace eukaryotic initiation factor 4G from the mRNA cap-binding complex in VAL cells.
• Knockdown of eukaryotic initiation factor 4E or re-expression of 4EBP1 sensitized VAL cells to apoptosis.

Conclusions:

• 4EBP1 deficiency is a naturally occurring mechanism of resistance to active-site mTOR inhibitors in lymphoma.
• Understanding 4EBP1 status may guide patient selection for mTOR inhibitor therapy.
• Targeting translation regulation pathways could enhance the efficacy of mTOR inhibitors in hematological cancers.